{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RomiDEPsin+10+MG%2FM2", "query": { "intervention": "RomiDEPsin 10 MG/M2" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 13, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RomiDEPsin+10+MG%2FM2&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-07T21:10:56.510Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04639843", "title": "Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult T-cell Leukemia/Lymphoma", "Extranodal NK-/T-cell Lymphoma, Nasal Type", "Enteropathy-Associated T-Cell Lymphoma", "Monomorphic Epiteliotrophic Intestinal T-cell Lymphoma", "Hepatosplenic T-cell Lymphoma" ], "interventions": [ { "name": "CC-486 (5-azacitidine)", "type": "DRUG" }, { "name": "Duvelisib", "type": "DRUG" }, { "name": "Romidepsin", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2022-11-03", "completion_date": "2022-11-03", "has_results": false, "last_update_posted_date": "2022-11-04", "last_synced_at": "2026-10-07T21:10:56.510Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04639843" }, { "nct_id": "NCT00765102", "title": "Trial of Romidepsin and Bortezomib for Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Romidepsin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2008-09-01", "completion_date": "2010-03-01", "has_results": true, "last_update_posted_date": "2019-11-25", "last_synced_at": "2026-10-07T21:10:56.510Z", "location_count": 12, "location_summary": "Loma Linda, California • Rancho Mirage, California • Santa Barbara, California + 9 more", "locations": [ { "city": "Loma Linda", "state": "California" }, { "city": "Rancho Mirage", "state": "California" }, { "city": "Santa Barbara", "state": "California" }, { "city": "West Hollywood", "state": "California" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00765102" }, { "nct_id": "NCT01947140", "title": "Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoid Malignancies", "Multiple Myeloma", "Lymphoma", "Hodgkin Lymphoma", "Non-hodgkin Lymphoma" ], "interventions": [ { "name": "Pralatrexate", "type": "DRUG" }, { "name": "Romidepsin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jennifer Amengual", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2013-09-09", "completion_date": "2022-09-01", "has_results": true, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-10-07T21:10:56.510Z", "location_count": 3, "location_summary": "Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01947140" }, { "nct_id": "NCT04447027", "title": "Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cutaneous T-Cell Lymphoma", "Mature T-cell Malignancies", "Peripheral T-Cell Lymphoma", "Relapsed/ Refractory T-cell Malignancies" ], "interventions": [ { "name": "Romidepsin", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "CC-486 (5-azacitidine)", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "EKG", "type": "DIAGNOSTIC_TEST" }, { "name": "Bone Marrow Aspiration/Biopsy", "type": "PROCEDURE" }, { "name": "MRI", "type": "DIAGNOSTIC_TEST" }, { "name": "Lumbar Puncture", "type": "PROCEDURE" }, { "name": "TTE", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2020-12-17", "completion_date": "2025-12-17", "has_results": true, "last_update_posted_date": "2026-08-13", "last_synced_at": "2026-10-07T21:10:56.510Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04447027" }, { "nct_id": "NCT03547700", "title": "Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma, T-Cell, Peripheral" ], "interventions": [ { "name": "Romidepsin", "type": "DRUG" }, { "name": "Ixazomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2018-09-26", "completion_date": "2020-08-27", "has_results": true, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-10-07T21:10:56.510Z", "location_count": 7, "location_summary": "Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 4 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03547700" }, { "nct_id": "NCT00379639", "title": "A Study of Romidepsin (Depsipeptide) in Combination With Gemcitabine in Patients With Pancreatic and Other Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Romidepsin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2006-07-01", "completion_date": "2008-07-01", "has_results": true, "last_update_posted_date": "2019-10-30", "last_synced_at": "2026-10-07T21:10:56.510Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00379639" }, { "nct_id": "NCT02181218", "title": "Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma, T-Cell, Cutaneous", "Lymphoma, T-Cell, Peripheral", "Hodgkin Disease", "Lymphoma, Large B-Cell, Diffuse" ], "interventions": [ { "name": "Romidepsin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2015-02-04", "completion_date": "2020-06-26", "has_results": false, "last_update_posted_date": "2020-11-17", "last_synced_at": "2026-10-07T21:10:56.510Z", "location_count": 2, "location_summary": "Chicago, Illinois • St Louis, Missouri", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02181218" }, { "nct_id": "NCT00106301", "title": "Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Renal Cell", "Prostatic Neoplasms" ], "interventions": [ { "name": "FK228 (romidepsin)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2004-04-01", "completion_date": "2006-09-01", "has_results": false, "last_update_posted_date": "2019-11-18", "last_synced_at": "2026-10-07T21:10:56.510Z", "location_count": 4, "location_summary": "Duarte, California • Gainesville, Florida • Chicago, Illinois + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00106301" }, { "nct_id": "NCT01482962", "title": "Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsed Peripheral T-Cell Lymphoma", "Refractory Peripheral T-Cell Lymphoma" ], "interventions": [ { "name": "Alisertib", "type": "DRUG" }, { "name": "Pralatrexate", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Romidepsin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 271, "start_date": "2012-06-11", "completion_date": "2017-12-18", "has_results": true, "last_update_posted_date": "2018-07-31", "last_synced_at": "2026-10-07T21:10:56.510Z", "location_count": 24, "location_summary": "Birmingham, Alabama • La Jolla, California • Orlando, Florida + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01482962" }, { "nct_id": "NCT03161223", "title": "Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma, T-Cell" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Pralatrexate", "type": "DRUG" }, { "name": "Romidepsin", "type": "DRUG" }, { "name": "5-Azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Virginia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 148, "start_date": "2018-05-30", "completion_date": "2023-02", "has_results": false, "last_update_posted_date": "2022-03-31", "last_synced_at": "2026-10-07T21:10:56.510Z", "location_count": 1, "location_summary": "Charlottesville, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03161223" } ] }